Last reviewed · How we verify
Albuterol and budesonide inhalation aerosol
Albuterol and budesonide inhalation aerosol is a Small molecule drug developed by AstraZeneca. It is currently FDA-approved. Also known as: PT027.
Albuterol and budesonide inhalation aerosol, marketed by AstraZeneca, is a combination therapy for respiratory conditions, currently holding a significant market position. The key strength of this product lies in its dual-action mechanism, which effectively addresses both bronchodilation and anti-inflammatory needs. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Albuterol and budesonide inhalation aerosol |
|---|---|
| Also known as | PT027 |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (PHASE3)
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (PHASE3)
- Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (PHASE2)
- A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma (PHASE3)
- Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. (PHASE3)
- Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol and budesonide inhalation aerosol CI brief — competitive landscape report
- Albuterol and budesonide inhalation aerosol updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Albuterol and budesonide inhalation aerosol
What is Albuterol and budesonide inhalation aerosol?
Who makes Albuterol and budesonide inhalation aerosol?
Is Albuterol and budesonide inhalation aerosol also known as anything else?
What development phase is Albuterol and budesonide inhalation aerosol in?
Related
- Manufacturer: AstraZeneca — full pipeline
- Also known as: PT027
- Compare: Albuterol and budesonide inhalation aerosol vs similar drugs
- Pricing: Albuterol and budesonide inhalation aerosol cost, discount & access